This innovative psoriasis treatment promises substantially fewer side effects, along with modest gains in efficacy.
Current biologic treatments offer many patients relief, but often do not induce long-term remission.
For a more comprehensive set of treatment options, patients would benefit from novel, efficacious, topical therapies without steroidal side effects and oral therapies that are safe and have an efficacy similar to that of biologics.
While bimekizumab is a late-class entrant providing incremental improvement over existing treatment options, it is expected to have best-in-class efficacy and fewer serious side effects.
Its dual inhibition of IL-17A and IL-17F differentiates its MOA from other biologics, and clinical trials results are promising. It also has the potential to benefit the ~30% of patients with concomitant psoriatic arthritis.
Bimekizumab will likely be used as a third- or fourth-line treatment for patients with primary non-response, loss of response or unacceptable side effects with other treatments.
Long-term efficacy and safety profile will be crucial to the use of bimekizumab.
Development also underway for:
Psoriatic arthritis (PsA)
Ankylosing spondylitis (AS)
Non-radiographic axial spondyloarthritis (nr-axSpA)
“It is highly likely to get approval. It is probably going to prove to be one of the fastest biologics we have and one of the most effective, but also it seems to be particularly effective for joint disease.”